Lisbeth Enggaard
YOU?
Author Swipe
View article: Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL Open
CNS involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare condition with no consensus on diagnosis and limited evidence for management and outcome. Here we report an international, multicenter, retrospective study conducted by…
View article: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial Open
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) are treated with fixed-duration B-cell lymphoma 2 inhibitors + CD20 monoclonal antibodies or continuous Bruton tyrosine kinase (BTK) inhibitors. Although continuous…
View article: First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Open
AbbVie, Janssen, and F Hoffmann-La Roche.
View article: Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S5. Stimulated cytokine response in patients with or without pre-treatment infections.
View article: Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S5. Baseline patient- and disease related characteristics for patients with or without history of infections.
View article: Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S4. Changes in immune cell activation marker expression during targeted treatment.
View article: Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S3. Supplementary Table S3. Representativeness of study participants.
View article: Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S5. Stimulated cytokine response in patients with or without pre-treatment infections.
View article: Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Purpose:Patients with chronic lymphocytic leukemia (CLL) have increased risk of severe infections. Although adaptive immune dysfunction is well described, clinical tools for identifying patients at risk are lacking, warranting investigatio…
View article: Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S1. Overview over the applied 10-color flow cytometry panel for the two tubes included in this study.
View article: Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S5. Baseline patient- and disease related characteristics for patients with or without history of infections.
View article: Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S1. Innate immune responses at baseline vs 2-3 cycles of BTKi.
View article: Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S2. Gating strategies for the immune cell subset populations included in this study.
View article: Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S6. Clinical trajectories with 3 years of follow up.
View article: Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S4. Baseline patient- and disease related characteristics.
View article: Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S3. Changes in innate immune cell subsets during targeted treatment and correlations with stimulated cytokine responses.
View article: Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S3. Supplementary Table S3. Representativeness of study participants.
View article: Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S2. Gating strategies for the immune cell subset populations included in this study.
View article: Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S1. Overview over the applied 10-color flow cytometry panel for the two tubes included in this study.
View article: Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S6. Clinical trajectories with 3 years of follow up.
View article: Supplementary Figure S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S2. Changes in innate immune responses during acalabrutinib and combined ibrutinib+venetoclax by sub cohort.
View article: Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S4. Changes in immune cell activation marker expression during targeted treatment.
View article: Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Purpose:Patients with chronic lymphocytic leukemia (CLL) have increased risk of severe infections. Although adaptive immune dysfunction is well described, clinical tools for identifying patients at risk are lacking, warranting investigatio…
View article: Supplementary Figure S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S2. Changes in innate immune responses during acalabrutinib and combined ibrutinib+venetoclax by sub cohort.
View article: Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S3. Changes in innate immune cell subsets during targeted treatment and correlations with stimulated cytokine responses.
View article: Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S4. Baseline patient- and disease related characteristics.
View article: Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S1. Innate immune responses at baseline vs 2-3 cycles of BTKi.
View article: P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL
P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL Open
Background: Infections are the major concern for patients with Chronic Lymphocytic Leukemia (CLL). Serious infections (1-month mortality rate: 10%) occur more frequently than progression to CLL treatment. We therefore developed the machine…
View article: P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Open
Background: CLL-cells interact with the surrounding immune microenvironment (IME) for survival. These interactions, however, induce immune changes that result in immune dysfunction, reflected in the increased risk of severe and fatal infec…
View article: S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL Open
Background: In patients with relapsed/refractory (RR) CLL efficacy and safety of MRD guided treatment cessation of venetoclax+ibrutinib (V+I) with the option to reinitiate V+I based on MRD reappearance was evaluated in the randomized Phase…